Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis

BackgroundChronic demyelination is a major contributor to axonal vulnerability in multiple sclerosis (MS). Therefore, remyelination could provide a potent neuroprotective strategy. The ReBUILD trial was the first study showing evidence for successful remyelination following treatment with clemastine...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neurology, neurosurgery and psychiatry Jg. 93; H. 9; S. 972 - 977
Hauptverfasser:	Abdelhak, Ahmed, Cordano, Christian, Boscardin, W John, Caverzasi, Eduardo, Kuhle, Jens, Chan, Brandon, Gelfand, Jeffrey M, Yiu, Hao H, Oertel, Frederike C, Beaudry-Richard, Alexandra, Condor Montes, Shivany, Oksenberg, Jorge R, Lario Lago, Argentina, Boxer, Adam, Rojas-Martinez, Julio C, Elahi, Fanny M, Chan, Jonah R, Green, Ari J
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England BMJ Publishing Group Ltd 01.09.2022 BMJ Publishing Group LTD
Schlagworte:	Biomarkers Body mass index Creatinine Magnetic resonance imaging Multiple sclerosis NEUROBIOLOGY Plasma Sample size Variance analysis United States > US San Francisco California California MULTIPLE SCLEROSIS NEUROBIOLOGY
ISSN:	0022-3050, 1468-330X, 1468-330X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	BackgroundChronic demyelination is a major contributor to axonal vulnerability in multiple sclerosis (MS). Therefore, remyelination could provide a potent neuroprotective strategy. The ReBUILD trial was the first study showing evidence for successful remyelination following treatment with clemastine in people with MS (pwMS) with no evidence of disease activity or progression (NEDAP). Whether remyelination was associated with neuroprotection remains unexplored.MethodsPlasma neurofilament light chain (NfL) levels were measured from ReBUILD trial’s participants. Mixed linear effect models were fit for individual patients, epoch and longitudinal measurements to compare NfL concentrations between samples collected during the active and placebo treatment period.ResultsNfL concentrations were 9.6% lower in samples collected during the active treatment with clemastine (n=53, geometric mean=6.33 pg/mL) compared to samples collected during treatment with placebo (n=73, 7.00 pg/mL) (B=−0.035 [−0.068 to −0.001], p=0.041). Applying age- and body mass index-standardised NfL Z-scores and percentiles revealed similar results (0.04 vs 0.35, and 27.5 vs 33.3, p=0.023 and 0.042, respectively). Higher NfL concentrations were associated with more delayed P100 latencies (B=1.33 [0.26 to 2.41], p=0.015). In addition, improvement of P100 latencies between visits was associated with a trend for lower NfL values (B=0.003 [−0.0004 to 0.007], p=0.081). Based on a Cohen’s d of 0.248, a future 1:1 parallel-arm placebo-controlled study using a remyelinating agent with comparable effect as clemastine would need 202 subjects per group to achieve 80% power.ConclusionsIn pwMS, treatment with the remyelinating agent clemastine was associated with a reduction of blood NfL, suggesting that neuroprotection is achievable and measurable with therapeutic remyelination.Trial registration number NCT02040298.
AbstractList	BackgroundChronic demyelination is a major contributor to axonal vulnerability in multiple sclerosis (MS). Therefore, remyelination could provide a potent neuroprotective strategy. The ReBUILD trial was the first study showing evidence for successful remyelination following treatment with clemastine in people with MS (pwMS) with no evidence of disease activity or progression (NEDAP). Whether remyelination was associated with neuroprotection remains unexplored.MethodsPlasma neurofilament light chain (NfL) levels were measured from ReBUILD trial’s participants. Mixed linear effect models were fit for individual patients, epoch and longitudinal measurements to compare NfL concentrations between samples collected during the active and placebo treatment period.ResultsNfL concentrations were 9.6% lower in samples collected during the active treatment with clemastine (n=53, geometric mean=6.33 pg/mL) compared to samples collected during treatment with placebo (n=73, 7.00 pg/mL) (B=−0.035 [−0.068 to −0.001], p=0.041). Applying age- and body mass index-standardised NfL Z-scores and percentiles revealed similar results (0.04 vs 0.35, and 27.5 vs 33.3, p=0.023 and 0.042, respectively). Higher NfL concentrations were associated with more delayed P100 latencies (B=1.33 [0.26 to 2.41], p=0.015). In addition, improvement of P100 latencies between visits was associated with a trend for lower NfL values (B=0.003 [−0.0004 to 0.007], p=0.081). Based on a Cohen’s d of 0.248, a future 1:1 parallel-arm placebo-controlled study using a remyelinating agent with comparable effect as clemastine would need 202 subjects per group to achieve 80% power.ConclusionsIn pwMS, treatment with the remyelinating agent clemastine was associated with a reduction of blood NfL, suggesting that neuroprotection is achievable and measurable with therapeutic remyelination.Trial registration numberNCT02040298. BackgroundChronic demyelination is a major contributor to axonal vulnerability in multiple sclerosis (MS). Therefore, remyelination could provide a potent neuroprotective strategy. The ReBUILD trial was the first study showing evidence for successful remyelination following treatment with clemastine in people with MS (pwMS) with no evidence of disease activity or progression (NEDAP). Whether remyelination was associated with neuroprotection remains unexplored.MethodsPlasma neurofilament light chain (NfL) levels were measured from ReBUILD trial’s participants. Mixed linear effect models were fit for individual patients, epoch and longitudinal measurements to compare NfL concentrations between samples collected during the active and placebo treatment period.ResultsNfL concentrations were 9.6% lower in samples collected during the active treatment with clemastine (n=53, geometric mean=6.33 pg/mL) compared to samples collected during treatment with placebo (n=73, 7.00 pg/mL) (B=−0.035 [−0.068 to −0.001], p=0.041). Applying age- and body mass index-standardised NfL Z-scores and percentiles revealed similar results (0.04 vs 0.35, and 27.5 vs 33.3, p=0.023 and 0.042, respectively). Higher NfL concentrations were associated with more delayed P100 latencies (B=1.33 [0.26 to 2.41], p=0.015). In addition, improvement of P100 latencies between visits was associated with a trend for lower NfL values (B=0.003 [−0.0004 to 0.007], p=0.081). Based on a Cohen’s d of 0.248, a future 1:1 parallel-arm placebo-controlled study using a remyelinating agent with comparable effect as clemastine would need 202 subjects per group to achieve 80% power.ConclusionsIn pwMS, treatment with the remyelinating agent clemastine was associated with a reduction of blood NfL, suggesting that neuroprotection is achievable and measurable with therapeutic remyelination.Trial registration number NCT02040298. Chronic demyelination is a major contributor to axonal vulnerability in multiple sclerosis (MS). Therefore, remyelination could provide a potent neuroprotective strategy. The ReBUILD trial was the first study showing evidence for successful remyelination following treatment with clemastine in people with MS (pwMS) with no evidence of disease activity or progression (NEDAP). Whether remyelination was associated with neuroprotection remains unexplored.BACKGROUNDChronic demyelination is a major contributor to axonal vulnerability in multiple sclerosis (MS). Therefore, remyelination could provide a potent neuroprotective strategy. The ReBUILD trial was the first study showing evidence for successful remyelination following treatment with clemastine in people with MS (pwMS) with no evidence of disease activity or progression (NEDAP). Whether remyelination was associated with neuroprotection remains unexplored.Plasma neurofilament light chain (NfL) levels were measured from ReBUILD trial's participants. Mixed linear effect models were fit for individual patients, epoch and longitudinal measurements to compare NfL concentrations between samples collected during the active and placebo treatment period.METHODSPlasma neurofilament light chain (NfL) levels were measured from ReBUILD trial's participants. Mixed linear effect models were fit for individual patients, epoch and longitudinal measurements to compare NfL concentrations between samples collected during the active and placebo treatment period.NfL concentrations were 9.6% lower in samples collected during the active treatment with clemastine (n=53, geometric mean=6.33 pg/mL) compared to samples collected during treatment with placebo (n=73, 7.00 pg/mL) (B=-0.035 [-0.068 to -0.001], p=0.041). Applying age- and body mass index-standardised NfL Z-scores and percentiles revealed similar results (0.04 vs 0.35, and 27.5 vs 33.3, p=0.023 and 0.042, respectively). Higher NfL concentrations were associated with more delayed P100 latencies (B=1.33 [0.26 to 2.41], p=0.015). In addition, improvement of P100 latencies between visits was associated with a trend for lower NfL values (B=0.003 [-0.0004 to 0.007], p=0.081). Based on a Cohen's d of 0.248, a future 1:1 parallel-arm placebo-controlled study using a remyelinating agent with comparable effect as clemastine would need 202 subjects per group to achieve 80% power.RESULTSNfL concentrations were 9.6% lower in samples collected during the active treatment with clemastine (n=53, geometric mean=6.33 pg/mL) compared to samples collected during treatment with placebo (n=73, 7.00 pg/mL) (B=-0.035 [-0.068 to -0.001], p=0.041). Applying age- and body mass index-standardised NfL Z-scores and percentiles revealed similar results (0.04 vs 0.35, and 27.5 vs 33.3, p=0.023 and 0.042, respectively). Higher NfL concentrations were associated with more delayed P100 latencies (B=1.33 [0.26 to 2.41], p=0.015). In addition, improvement of P100 latencies between visits was associated with a trend for lower NfL values (B=0.003 [-0.0004 to 0.007], p=0.081). Based on a Cohen's d of 0.248, a future 1:1 parallel-arm placebo-controlled study using a remyelinating agent with comparable effect as clemastine would need 202 subjects per group to achieve 80% power.In pwMS, treatment with the remyelinating agent clemastine was associated with a reduction of blood NfL, suggesting that neuroprotection is achievable and measurable with therapeutic remyelination.CONCLUSIONSIn pwMS, treatment with the remyelinating agent clemastine was associated with a reduction of blood NfL, suggesting that neuroprotection is achievable and measurable with therapeutic remyelination.NCT02040298.TRIAL REGISTRATION NUMBERNCT02040298. Chronic demyelination is a major contributor to axonal vulnerability in multiple sclerosis (MS). Therefore, remyelination could provide a potent neuroprotective strategy. The ReBUILD trial was the first study showing evidence for successful remyelination following treatment with clemastine in people with MS (pwMS) with no evidence of disease activity or progression (NEDAP). Whether remyelination was associated with neuroprotection remains unexplored. Plasma neurofilament light chain (NfL) levels were measured from ReBUILD trial's participants. Mixed linear effect models were fit for individual patients, epoch and longitudinal measurements to compare NfL concentrations between samples collected during the active and placebo treatment period. NfL concentrations were 9.6% lower in samples collected during the active treatment with clemastine (n=53, geometric mean=6.33 pg/mL) compared to samples collected during treatment with placebo (n=73, 7.00 pg/mL) (B=-0.035 [-0.068 to -0.001], p=0.041). Applying age- and body mass index-standardised NfL Z-scores and percentiles revealed similar results (0.04 vs 0.35, and 27.5 vs 33.3, p=0.023 and 0.042, respectively). Higher NfL concentrations were associated with more delayed P100 latencies (B=1.33 [0.26 to 2.41], p=0.015). In addition, improvement of P100 latencies between visits was associated with a trend for lower NfL values (B=0.003 [-0.0004 to 0.007], p=0.081). Based on a Cohen's d of 0.248, a future 1:1 parallel-arm placebo-controlled study using a remyelinating agent with comparable effect as clemastine would need 202 subjects per group to achieve 80% power. In pwMS, treatment with the remyelinating agent clemastine was associated with a reduction of blood NfL, suggesting that neuroprotection is achievable and measurable with therapeutic remyelination. NCT02040298.
Author	Chan, Brandon Gelfand, Jeffrey M Kuhle, Jens Green, Ari J Beaudry-Richard, Alexandra Rojas-Martinez, Julio C Boxer, Adam Caverzasi, Eduardo Yiu, Hao H Oksenberg, Jorge R Boscardin, W John Elahi, Fanny M Abdelhak, Ahmed Lario Lago, Argentina Cordano, Christian Condor Montes, Shivany Chan, Jonah R Oertel, Frederike C
Author_xml	– sequence: 1 givenname: Ahmed orcidid: 0000-0001-9731-4169 surname: Abdelhak fullname: Abdelhak, Ahmed organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA – sequence: 2 givenname: Christian surname: Cordano fullname: Cordano, Christian organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA – sequence: 3 givenname: W John surname: Boscardin fullname: Boscardin, W John organization: Departments of Medicine and Epidemiology & Biostatistics, University of California at San Francisco, San Francisco, California, USA – sequence: 4 givenname: Eduardo orcidid: 0000-0002-0350-0460 surname: Caverzasi fullname: Caverzasi, Eduardo organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA – sequence: 5 givenname: Jens surname: Kuhle fullname: Kuhle, Jens organization: Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), University Hospital and University of Basel, Basel, Switzerland – sequence: 6 givenname: Brandon surname: Chan fullname: Chan, Brandon organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA – sequence: 7 givenname: Jeffrey M orcidid: 0000-0002-5121-3319 surname: Gelfand fullname: Gelfand, Jeffrey M organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA – sequence: 8 givenname: Hao H surname: Yiu fullname: Yiu, Hao H organization: Department of Biology, University of Maryland, College Park, Maryland, USA – sequence: 9 givenname: Frederike C surname: Oertel fullname: Oertel, Frederike C organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA – sequence: 10 givenname: Alexandra surname: Beaudry-Richard fullname: Beaudry-Richard, Alexandra organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA – sequence: 11 givenname: Shivany surname: Condor Montes fullname: Condor Montes, Shivany organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA – sequence: 12 givenname: Jorge R surname: Oksenberg fullname: Oksenberg, Jorge R organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA – sequence: 13 givenname: Argentina surname: Lario Lago fullname: Lario Lago, Argentina organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA – sequence: 14 givenname: Adam surname: Boxer fullname: Boxer, Adam organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA – sequence: 15 givenname: Julio C surname: Rojas-Martinez fullname: Rojas-Martinez, Julio C organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA – sequence: 16 givenname: Fanny M surname: Elahi fullname: Elahi, Fanny M organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA – sequence: 17 givenname: Jonah R surname: Chan fullname: Chan, Jonah R organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA – sequence: 18 givenname: Ari J surname: Green fullname: Green, Ari J email: agreen@ucsf.edu organization: Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco (UCSF), San Francisco, California, USA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35710320$$D View this record in MEDLINE/PubMed
BookMark	eNp9kU9v1DAQxS3Uim4Ld07IEpceSPG_xMkRVS0gVYIDSNwsO5nseuXYwXYo-xn6pUmaVkiV6FyskX_vaWbeKTrywQNCbyi5oJRXH_bejwUjjBWcNYzRF2hDRVUXnJOfR2hD7n9ISU7QaUp7slTdvEQnvJSUcEY26O6b02nQ2MMUQ2-dHsBn7Ox2l3G709ZjB7_BJZym7RZSXkH9J3jtcMraWGfzAffBuXBr_RbnHUQ9wpRtiyMMB3DW62yDx7PXCGF0gG9t3uFhctkuXWodxJBseoWOe-0SvH54z9CP66vvl5-Lm6-fvlx-vCmM4CIXrRCiNoyZjgB0tG64BtmVdS9ZpUXDZEehltQQo7VkrC0rSUTFpelLpjvZ8zN0vvqOMfya5qXUYFMLzmkPYUqKVbIWbDGe0XdP0H2Y4rz7TElKy4o1tHmWqqRsyqYUi9fbB2oyA3RqjHbQ8aAew5iBagXa-RwpQq9am-9vl6O2TlGiltTVkrpaUldr6rOQPBE-ej8jeb9KzLD_N-1_8b9_h8A4
CitedBy_id	crossref_primary_10_1093_brain_awaf144 crossref_primary_10_1038_s41467_024_53429_5 crossref_primary_10_1016_j_msard_2025_106655 crossref_primary_10_1016_j_bbih_2024_100891 crossref_primary_10_3389_fnmol_2023_1279985 crossref_primary_10_1016_j_pbb_2024_173824 crossref_primary_10_1080_01616412_2025_2507756 crossref_primary_10_1097_WNO_0000000000002149 crossref_primary_10_3390_ijms24076373 crossref_primary_10_1002_ana_27200 crossref_primary_10_1126_scitranslmed_adl4616 crossref_primary_10_1136_jnnp_2023_331183 crossref_primary_10_1016_j_scib_2023_07_009 crossref_primary_10_1093_brain_awaf224 crossref_primary_10_1016_j_ensci_2025_100550
Cites_doi	10.1212/NXI.0000000000001155 10.1073/pnas.2115973119 10.1002/glia.22597 10.1016/S1474-4422(22)00009-6 10.1371/journal.pone.0235615 10.3390/biomedicines8090312 10.1126/science.1218071 10.1038/nm.3618 10.1007/s12035-014-9019-8 10.1093/brain/awn080 10.1212/WNL.0000000000007032 10.1523/JNEUROSCI.1530-18.2019 10.1016/S0140-6736(17)32346-2 10.1016/S1474-4422(10)70064-8 10.1016/j.neuroimage.2020.117471 10.1016/S1474-4422(14)70256-X 10.7554/eLife.18246 10.1038/s41598-018-33158-8 10.1001/jamaneurol.2019.2137 10.3758/BF03193146 10.1002/dad2.12168 10.1093/brain/awx312 10.1038/nrneurol.2012.168 10.1038/s41582-018-0058-z 10.1177/1352458519885613 10.3758/BRM.41.4.1149
ContentType	Journal Article
Copyright	Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. 2022 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Copyright_xml	– notice: Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2022 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
DBID	AAYXX CITATION NPM 3V. 7RV 7X7 7XB 88E 88G 88I 8AF 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR BTHHO CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. KB0 M0S M1P M2M M2P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8
DOI	10.1136/jnnp-2022-329221
DatabaseName	CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central BMJ Journals ProQuest One Community College ProQuest Central Korea ProQuest Health & Medical Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Psychology Database Science Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic
DatabaseTitle	CrossRef PubMed ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest AP Science ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition BMJ Journals ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	ProQuest One Psychology MEDLINE - Academic ProQuest One Psychology PubMed
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1468-330X
EndPage	977
ExternalDocumentID	35710320 10_1136_jnnp_2022_329221 jnnp
Genre	Journal Article
GeographicLocations	United States--US San Francisco California California
GeographicLocations_xml	– name: San Francisco California – name: United States--US – name: California
GrantInformation_xml	– fundername: National Multiple Sclerosis Society grantid: SI-2001-3571 funderid: http://dx.doi.org/10.13039/100000890 – fundername: National Institute of Health grantid: K23AG059888 – fundername: NIA NIH HHS grantid: K23 AG059888 – fundername: NINDS NIH HHS grantid: R35 NS111644
GroupedDBID	--- .55 .GJ .VT 0R~ 18M 29L 2WC 354 39C 3O- 4.4 40O 41~ 53G 5GY 5RE 5VS 7RV 7X7 7~S 88E 88I 8AF 8FI 8FJ 8R4 8R5 AAHLL AAKAS AAOJX AAUVZ AAWJN AAWTL ABAAH ABIVO ABJNI ABKDF ABMQD ABOCM ABUWG ABVAJ ACGFO ACGFS ACGOD ACGTL ACHTP ACMFJ ACOAB ACOFX ACQSR ACTZY ADBBV ADCEG ADFRT ADUGQ ADZCM AEKJL AENEX AFKRA AFWFF AGQPQ AHMBA AHNKE AHQMW AI. AJYBZ AKKEP ALIPV ALMA_UNASSIGNED_HOLDINGS AZFZN AZQEC BAWUL BENPR BLJBA BOMFT BPHCQ BTFSW BTHHO BVXVI C45 CAG CCPQU COF CS3 CXRWF DIK DU5 DWQXO E3Z EBS EJD EX3 F5P FEDTE FYUFA GNUQQ GX1 H13 HAJ HCIFZ HMCUK HVGLF HYE HZ~ IAO IEA IHR INH INR IOF IPO IPY ITC J5H KQ8 L7B M1P M2M M2P N9A NAPCQ NTWIH NXWIF O9- OK1 OMB OMG OVD P2P PCD PHGZT PQQKQ PROAC PSQYO PSYQQ Q2X R53 RHI RMJ RPM RV8 SJN TEORI TR2 UKHRP UPT UYXKK V24 VH1 VM9 VVN W8F WH7 WOW X7M YFH YQT YQY ZGI AAYXX ACQHZ AERUA AFFHD CITATION PHGZM PJZUB PPXIY NPM 3V. 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8
ID	FETCH-LOGICAL-b434t-c4448b22bd0eed1893ae7d58f726a4927d1e871b0baa722c56704637bf52ad7f3
IEDL.DBID	BENPR
ISICitedReferencesCount	20
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000813064100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0022-3050 1468-330X
IngestDate	Sun Nov 09 03:24:41 EST 2025 Tue Oct 07 07:09:46 EDT 2025 Tue Oct 07 07:06:34 EDT 2025 Mon Jul 21 05:44:18 EDT 2025 Sat Nov 29 02:37:35 EST 2025 Tue Nov 18 20:53:27 EST 2025 Thu Apr 24 22:51:00 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	9
Keywords	MULTIPLE SCLEROSIS NEUROBIOLOGY
Language	English
License	Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-b434t-c4448b22bd0eed1893ae7d58f726a4927d1e871b0baa722c56704637bf52ad7f3
Notes	Original research ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0002-0350-0460 0000-0002-5121-3319 0000-0001-9731-4169
OpenAccessLink	https://www.ncbi.nlm.nih.gov/pmc/articles/9984688
PMID	35710320
PQID	2677959543
PQPubID	2041879
PageCount	6
ParticipantIDs	proquest_miscellaneous_2678421893 proquest_journals_2711562919 proquest_journals_2677959543 pubmed_primary_35710320 crossref_citationtrail_10_1136_jnnp_2022_329221 crossref_primary_10_1136_jnnp_2022_329221 bmj_journals_10_1136_jnnp_2022_329221
PublicationCentury	2000
PublicationDate	2022-09-01
PublicationDateYYYYMMDD	2022-09-01
PublicationDate_xml	– month: 09 year: 2022 text: 2022-09-01 day: 01
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: London
PublicationTitle	Journal of neurology, neurosurgery and psychiatry
PublicationTitleAbbrev	J Neurol Neurosurg Psychiatry
PublicationTitleAlternate	J Neurol Neurosurg Psychiatry
PublicationYear	2022
Publisher	BMJ Publishing Group Ltd BMJ Publishing Group LTD
Publisher_xml	– name: BMJ Publishing Group Ltd – name: BMJ Publishing Group LTD
References	Sarrazin, Chavret-Reculon, Bachelin (R23) 2022; 119 Khalil, Teunissen, Otto (R11) 2018; 14 Huss, Senel, Abdelhak (R15) 2020; 8 Thebault MA, Fereshtehnejad, Tessier (R25) 2020; 2020 Kuhle, Plavina, Barro (R13) 2019; 1352458519885613 Faul, Erdfelder, Lang (R20) 2007; 39 Koch-Henriksen, Sørensen (R1) 2010; 9 Lassmann (R2) 2014; 62 Green, Gelfand, Cree (R10) 2017; 390 Mei, Fancy, Shen (R6) 2014; 20 Goldman, Nedergaard, Windrem (R7) 2012; 338 Kuhle, Kropshofer, Haering (R14) 2019; 92 Benkert, Meier, Schaedelin (R17) 2022; 21 Irvine, Blakemore (R5) 2008; 131 Abdelhak, Huss, Kassubek (R12) 2018; 8 Mahad, Trapp, Lassmann (R21) 2015; 14 Cree, Niu, Hoi (R9) 2018; 141 Klistorner, Klistorner, You (R22) 2022; 9 Mei, Lehmann-Horn, Shen (R4) 2016; 5 Cerri, Puonti, Meier (R18) 2021; 225 Rankin, Mei, Kim (R8) 2019; 39 Lassmann, van Horssen, Mahad (R3) 2012; 8 Cantó, Barro, Zhao (R16) 2019; 76 Caverzasi, Cordano, Zhu (R19) 2020; 15 Ashton, Suárez-Calvet, Karikari (R24) 2021; 13 Apolloni, Fabbrizio, Parisi (R26) 2016; 53 2023051801202574000_93.9.972.11 2023051801202574000_93.9.972.12 2023051801202574000_93.9.972.10 2023051801202574000_93.9.972.16 2023051801202574000_93.9.972.13 2023051801202574000_93.9.972.14 2023051801202574000_93.9.972.1 2023051801202574000_93.9.972.19 2023051801202574000_93.9.972.5 2023051801202574000_93.9.972.2 2023051801202574000_93.9.972.17 2023051801202574000_93.9.972.3 2023051801202574000_93.9.972.18 2023051801202574000_93.9.972.8 2023051801202574000_93.9.972.9 2023051801202574000_93.9.972.6 2023051801202574000_93.9.972.7 Mei (2023051801202574000_93.9.972.4) 2016; 5 2023051801202574000_93.9.972.23 2023051801202574000_93.9.972.20 2023051801202574000_93.9.972.21 2023051801202574000_93.9.972.26 2023051801202574000_93.9.972.25 Klistorner (2023051801202574000_93.9.972.22) 2022; 9 Ashton (2023051801202574000_93.9.972.24) 2021; 13 Huss (2023051801202574000_93.9.972.15) 2020; 8
References_xml	– volume: 9 year: 2022 ident: R22 article-title: Long-term effect of permanent demyelination on axonal survival in multiple sclerosis publication-title: Neurol Neuroimmunol Neuroinflamm doi: 10.1212/NXI.0000000000001155 – volume: 119 year: 2022 ident: R23 article-title: Failed remyelination of the nonhuman primate optic nerve leads to axon degeneration, retinal damages, and visual dysfunction publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.2115973119 – volume: 62 start-page: 1816 year: 2014 ident: R2 article-title: Mechanisms of white matter damage in multiple sclerosis publication-title: Glia doi: 10.1002/glia.22597 – volume: 21 start-page: 246 year: 2022 ident: R17 article-title: Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study publication-title: Lancet Neurol doi: 10.1016/S1474-4422(22)00009-6 – volume: 15 year: 2020 ident: R19 article-title: Imaging correlates of visual function in multiple sclerosis publication-title: PLoS One doi: 10.1371/journal.pone.0235615 – volume: 8 year: 2020 ident: R15 article-title: Longitudinal serum neurofilament levels of multiple sclerosis patients before and after treatment with first-line immunomodulatory therapies publication-title: Biomedicines doi: 10.3390/biomedicines8090312 – volume: 2020 year: 2020 ident: R25 article-title: P0051 - Comparison of serum and csf fluid biomarkers for predicting long term disease progression in MS publication-title: MSVirtual – volume: 338 start-page: 491 year: 2012 ident: R7 article-title: Glial progenitor cell-based treatment and modeling of neurological disease publication-title: Science doi: 10.1126/science.1218071 – volume: 20 start-page: 954 year: 2014 ident: R6 article-title: Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis publication-title: Nat Med doi: 10.1038/nm.3618 – volume: 53 start-page: 518 year: 2016 ident: R26 article-title: Clemastine Confers Neuroprotection and Induces an Anti-Inflammatory Phenotype in SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis publication-title: Mol Neurobiol doi: 10.1007/s12035-014-9019-8 – volume: 131 start-page: 1464 year: 2008 ident: R5 article-title: Remyelination protects axons from demyelination-associated axon degeneration publication-title: Brain doi: 10.1093/brain/awn080 – volume: 92 start-page: e1007 year: 2019 ident: R14 article-title: Blood neurofilament light chain as a biomarker of MS disease activity and treatment response publication-title: Neurology doi: 10.1212/WNL.0000000000007032 – volume: 39 start-page: 2184 year: 2019 ident: R8 article-title: Selective estrogen receptor modulators enhance CNS remyelination independent of estrogen receptors publication-title: J Neurosci doi: 10.1523/JNEUROSCI.1530-18.2019 – volume: 390 start-page: 2481 year: 2017 ident: R10 article-title: Clemastine fumarate as a remyelinating therapy for multiple sclerosis (rebuild): a randomised, controlled, double-blind, crossover trial publication-title: Lancet doi: 10.1016/S0140-6736(17)32346-2 – volume: 9 start-page: 520 year: 2010 ident: R1 article-title: The changing demographic pattern of multiple sclerosis epidemiology publication-title: Lancet Neurol doi: 10.1016/S1474-4422(10)70064-8 – volume: 1352458519885613 year: 2019 ident: R13 article-title: Neurofilament light levels are associated with long-term outcomes in multiple sclerosis publication-title: Mult Scler – volume: 225 year: 2021 ident: R18 article-title: A contrast-adaptive method for simultaneous whole-brain and lesion segmentation in multiple sclerosis publication-title: Neuroimage doi: 10.1016/j.neuroimage.2020.117471 – volume: 14 start-page: 183 year: 2015 ident: R21 article-title: Pathological mechanisms in progressive multiple sclerosis publication-title: Lancet Neurol doi: 10.1016/S1474-4422(14)70256-X – volume: 5 year: 2016 ident: R4 article-title: Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery publication-title: Elife doi: 10.7554/eLife.18246 – volume: 8 year: 2018 ident: R12 article-title: Serum GFAP as a biomarker for disease severity in multiple sclerosis publication-title: Sci Rep doi: 10.1038/s41598-018-33158-8 – volume: 76 start-page: 1359 year: 2019 ident: R16 article-title: Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2019.2137 – volume: 39 start-page: 175 year: 2007 ident: R20 article-title: G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences publication-title: Behav Res Methods doi: 10.3758/BF03193146 – volume: 13 year: 2021 ident: R24 article-title: Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration publication-title: Alzheimers Dement doi: 10.1002/dad2.12168 – volume: 141 start-page: 85 year: 2018 ident: R9 article-title: Clemastine rescues myelination defects and promotes functional recovery in hypoxic brain injury publication-title: Brain doi: 10.1093/brain/awx312 – volume: 8 start-page: 647 year: 2012 ident: R3 article-title: Progressive multiple sclerosis: pathology and pathogenesis publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2012.168 – volume: 14 start-page: 577 year: 2018 ident: R11 article-title: Neurofilaments as biomarkers in neurological disorders publication-title: Nat Rev Neurol doi: 10.1038/s41582-018-0058-z – ident: 2023051801202574000_93.9.972.14 doi: 10.1212/WNL.0000000000007032 – volume: 13 year: 2021 ident: 2023051801202574000_93.9.972.24 article-title: Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration publication-title: Alzheimers Dement – ident: 2023051801202574000_93.9.972.25 – ident: 2023051801202574000_93.9.972.13 doi: 10.1177/1352458519885613 – ident: 2023051801202574000_93.9.972.26 doi: 10.1007/s12035-014-9019-8 – ident: 2023051801202574000_93.9.972.8 doi: 10.1523/JNEUROSCI.1530-18.2019 – volume: 8 year: 2020 ident: 2023051801202574000_93.9.972.15 article-title: Longitudinal serum neurofilament levels of multiple sclerosis patients before and after treatment with first-line immunomodulatory therapies publication-title: Biomedicines doi: 10.3390/biomedicines8090312 – ident: 2023051801202574000_93.9.972.11 doi: 10.1038/s41582-018-0058-z – ident: 2023051801202574000_93.9.972.18 doi: 10.1016/j.neuroimage.2020.117471 – ident: 2023051801202574000_93.9.972.19 doi: 10.1371/journal.pone.0235615 – ident: 2023051801202574000_93.9.972.16 doi: 10.1001/jamaneurol.2019.2137 – ident: 2023051801202574000_93.9.972.12 doi: 10.1038/s41598-018-33158-8 – ident: 2023051801202574000_93.9.972.6 doi: 10.1038/nm.3618 – ident: 2023051801202574000_93.9.972.2 doi: 10.1002/glia.22597 – ident: 2023051801202574000_93.9.972.23 doi: 10.1073/pnas.2115973119 – ident: 2023051801202574000_93.9.972.3 doi: 10.1038/nrneurol.2012.168 – ident: 2023051801202574000_93.9.972.17 doi: 10.1016/S1474-4422(22)00009-6 – ident: 2023051801202574000_93.9.972.10 doi: 10.1016/S0140-6736(17)32346-2 – volume: 5 year: 2016 ident: 2023051801202574000_93.9.972.4 article-title: Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery publication-title: Elife doi: 10.7554/eLife.18246 – ident: 2023051801202574000_93.9.972.20 doi: 10.3758/BRM.41.4.1149 – ident: 2023051801202574000_93.9.972.5 doi: 10.1093/brain/awn080 – ident: 2023051801202574000_93.9.972.7 doi: 10.1126/science.1218071 – ident: 2023051801202574000_93.9.972.9 doi: 10.1093/brain/awx312 – ident: 2023051801202574000_93.9.972.21 doi: 10.1016/S1474-4422(14)70256-X – ident: 2023051801202574000_93.9.972.1 doi: 10.1016/S1474-4422(10)70064-8 – volume: 9 year: 2022 ident: 2023051801202574000_93.9.972.22 article-title: Long-term effect of permanent demyelination on axonal survival in multiple sclerosis publication-title: Neurol Neuroimmunol Neuroinflamm doi: 10.1212/NXI.0000000000001155
SSID	ssj0000089
Score	2.4949872
Snippet	BackgroundChronic demyelination is a major contributor to axonal vulnerability in multiple sclerosis (MS). Therefore, remyelination could provide a potent... Chronic demyelination is a major contributor to axonal vulnerability in multiple sclerosis (MS). Therefore, remyelination could provide a potent...
SourceID	proquest pubmed crossref bmj
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	972
SubjectTerms	Biomarkers Body mass index Creatinine Magnetic resonance imaging Multiple sclerosis NEUROBIOLOGY Plasma Sample size Variance analysis
Title	Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis
URI	https://jnnp.bmj.com/content/93/9/972.full https://www.ncbi.nlm.nih.gov/pubmed/35710320 https://www.proquest.com/docview/2677959543 https://www.proquest.com/docview/2711562919 https://www.proquest.com/docview/2678421893
Volume	93
WOSCitedRecordID	wos000813064100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1468-330X dateEnd: 20250607 omitProxy: false ssIdentifier: ssj0000089 issn: 0022-3050 databaseCode: 7X7 dateStart: 19440701 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1468-330X dateEnd: 20250607 omitProxy: false ssIdentifier: ssj0000089 issn: 0022-3050 databaseCode: 7RV dateStart: 19440701 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1468-330X dateEnd: 20250607 omitProxy: false ssIdentifier: ssj0000089 issn: 0022-3050 databaseCode: BENPR dateStart: 19440701 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1468-330X dateEnd: 20250607 omitProxy: false ssIdentifier: ssj0000089 issn: 0022-3050 databaseCode: M2M dateStart: 19440701 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1468-330X dateEnd: 20250607 omitProxy: false ssIdentifier: ssj0000089 issn: 0022-3050 databaseCode: M2P dateStart: 19440701 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB7RLkJceMMWlpWR4MAhaur4kZwQoF1xoFW1glVvkZM40FWblqZd2N_An2bGccIiQS9cLEV2LMvzjWfGM54BeGkKlHlJjGZqaBQaKIoHhqq5S4OcZYQJlXMXnH_Uk0k8myVTf-FW-7DK9kx0B3WxyumOfMg16i6KJ6PkzfpbQFWjyLvqS2j04IAylYk-HLw7mUzPrinAcdLlCw9l2DoqIzW8qKo1YoQ6eMIpV2gvW178KZ7-oXM62XN6939XfQ_ueK2TvW1gch9u2OoB3Bp7v_pD-DlFJXppmMtuWc4RJSiL2IIMd5Z_NfOKLSi4qGb17gs5pJqB5gep8Qz1Sxdhe8VKBNXqOwpDdu1ZF9vY5RW9encYYDhXE7XO6AqYtQGNrMaF4ZbM60fw-fTk0_sPgS_TEGQiEtsgF2jiZZxnRYgCd4QKkLG6kHGpuTIi4boYWTTLsjAzRnOeS6UpTZnOSslNocvoMfSrVWUPgYnSqiiXeEaYQkiDQyxPSquTkczCXBcDeIU0Sj2b1amzYCKVEi1TomXa0HIAw5aKae5znVPJjcWeP153f6ybPB97xh61xP69FK40lW2XIvp7dweEAbzoupGVyT9jKrvauSliwWkDB_CkwVu3lkhqSn0YPt0_-TO47SDtguCOoL_d7OxzuJlfbuf15hh6-uyc2pl2bXzs-QW_xnzs2ukvLx4dXw
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB61BQGX8i4LBYxEDxyiTZzYTg4IIaBq1e2qQqXqLXUSh261m91udlv2N_S_8BuZcR4UCfbWA2fbI8v-5uUZzwC81RnqvChEN9XVEh0UyR1N3dyFRs7SgXalDRcc9VS_Hx4fRwcr8LP5C0NplY1MtII6G6f0Rt7lCm0XySMv-jA5d6hrFEVXmxYaFSz2zOISXbby_e5nvN8tzre_HH7acequAk4S-MHMSQP0SBLOk8xF_eChvtZGZSLMFZc6iLjKPINeROImWivOUyEVVdVSSS64zlTuI91VuIVy3KMUMvX16Jq5HUZtdXJXuE1Y1Jfds6KYICJpgEecKpOuJqOzP5XhPyxcq-m27_9vZ_QA1mubmn2smOAhrJjiEdzZr7MGHsPVAboII81s7c58gDyAmpYN6VmCpad6ULAhpU6VrJx_p3BbNVH_ICeFofVs84cXLEeWGV-iqmfXPq2xqRkt6E-_RThDWlVOPqMHbtaka7ISN4ZXMCifwLcbOYqnsFaMC_MMWJAb6acCJaDOAqFxiuFRblTkicRNVdaBLcREXAuRMrb-mS9jwk5M2Ikr7HSg26AmTutK7tRQZLhkxbt2xaSqYrJk7mYDrt9b4VJRU3oR-H8fboHXgTftMAoqij7pwoznlkQYcDrADmxU-G734gtFhR3d58uJv4a7O4f7vbi32997AfcsO9l0v01Ym03n5iXcTi9mg3L6yvIlg5ObBvkvx650GQ
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxEB61BVW98IYGChiJHjissvH6sXtACFEiqjZRDoB6W7y7XkiVbEI2oeQ38I_4dcx4HxQJcuuBs-2RZX_z8oxnAJ6bDHVeFKKb6huFDorinqFu7tIgZxlhfOXCBR9P9XAYnp1Foy342fyFobTKRiY6QZ3NUnoj73KNtoviUS_q5nVaxOio_2r-1aMOUhRpbdppVBA5sesLdN_Kl8dHeNeHnPffvn_zzqs7DHiJCMTSSwV6JwnnSeajruih7jZWZzLMNVdGRFxnPYseReInxmjOU6k0VdjSSS65yXQeIN1tuKaFlNQ9YcAHl0zvMGorlfvSb0KkgeqeF8Uc0UkDPOJUpXQ7mZ7_qRj_Ye06rde_-T-f1y24Udva7HXFHLdhyxZ3YHdQZxPchR8jdB2mhrmanvkYeQM1MJvQcwVLv5hxwSaUUlWycvWZwnDVRPOdnBeGVrXLK16zHFlpdoEmALv0mY0t7HRNf_0d8hnSqnL1GT18syaNk5W4MbyOcXkPPlzJUdyHnWJW2H1gIrcqSCVKRpMJaXCK5VFuddSTiZ_qrAOHiI-4Fi5l7Py2QMWEo5hwFFc46kC3QVCc1hXeqdHIZMOKF-2KeVXdZMPcgwZov7fClaZm9VIEfx9uQdiBZ-0wCjCKSpnCzlaORCg4HWAHHlRYb_cSSE0FH_2Hm4k_hV3Ednx6PDx5BHuOs1wW4AHsLBcr-xiup9-W43LxxLEog09XjfFfwRV8sA
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+neurofilament+light+chain+levels+suggest+neuroaxonal+stability+following+therapeutic+remyelination+in+people+with+multiple+sclerosis&rft.jtitle=Journal+of+neurology%2C+neurosurgery+and+psychiatry&rft.au=Abdelhak%2C+Ahmed&rft.au=Cordano%2C+Christian&rft.au=Boscardin%2C+W+John&rft.au=Caverzasi%2C+Eduardo&rft.date=2022-09-01&rft.pub=BMJ+Publishing+Group+Ltd&rft.issn=0022-3050&rft.eissn=1468-330X&rft.volume=93&rft.issue=9&rft.spage=972&rft.epage=977&rft_id=info:doi/10.1136%2Fjnnp-2022-329221&rft_id=info%3Apmid%2F35710320&rft.externalDBID=jnnp&rft.externalDocID=jnnp
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3050&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3050&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3050&client=summon